IOVA

Iovance Biotherapeutics Stock Price

29.14
0.02 (0.07%)
Upgrade to Real-Time
Afterhours (Closed)
29.12
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Iovance Biotherapeutics Inc IOVA NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.03 0.1% 29.12 28.72 29.68 29.26 29.09 20:00:00
Bid Price Ask Price Spread Spread % News
29.14 29.49 0.35 1.19% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
10,045 847,826 $ 29.20 $ 24,754,014 2,876,926 17.67 - 42.00
Last Trade Time Type Quantity Stock Price Currency
19:55:02 formt 200 $ 29.14 USD

Iovance Biotherapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 4.26B 146.34M 136.47M $ - $ - -1.59 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Iovance Biotherapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical IOVA Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week27.6129.8026.3428.011,854,8071.515.47%
1 Month31.2133.3726.3429.072,280,680-2.09-6.7%
3 Months31.4542.0026.3432.572,170,483-2.33-7.41%
6 Months25.1942.0018.7030.552,006,3273.9315.6%
1 Year24.5142.0017.6727.521,628,7654.6118.81%
3 Years7.3542.004.4519.331,266,80121.77296.19%
5 Years8.9142.004.2417.53891,72820.21226.82%

Iovance Biotherapeutics Description

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. It's lead pipeline candidate, LN-145, is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) to treat patients with refractory metastatic melanoma.


Your Recent History
NASDAQ
IOVA
Iovance Bi..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.